In early disease, prospective clinical trials could select patients with HER2DX low-risk disease, HER2DX ERBB2 mRNA-high and HER2DX pCR-high tumours and demonstrate that trastuzumab-pertuzumab treatment without chemotherapy achieves outstanding long-term survival outcomes. This evidence concerns the gene ERBB2 and neoplasm.